EYE » Topics » Refractive sales rose 1.5% to $118.3 million.
This excerpt taken from the EYE 8-K filed Aug 4, 2008.
Refractive sales rose 1.5% to $118.3 million.
Procedures, implants and related sales were $77.4 million, down slightly from $78.1 million one year ago as U.S. excimer
and refractive IOL market weakness was mostly offset by increased global penetration of the companys IntraLase®technology and international growth of its refractive procedures
AMOs U.S. excimer procedure volumes declined approximately 20% in the second quarter and approximately 6% for the trailing 12 months ended June 27, 2008.
For the trailing 12 months ended June 27, 2008, the companys U.S. custom mix was 67%; the second-quarter custom mix was 68%, compared to 65% in the year-ago quarter.
AMOs U.S. femtosecond procedure volumes grew approximately 14% in the second quarter and approximately 25% for the trailing 12 months ended June 27,
2008, on a pro forma basis.
AMOs international procedure, implant and related sales hit a new high in the second quarter, at $31.6 million, up 45.1%.
System sales rose 10.1% to $31.3 million, reflecting the continued demand for the companys iLASIKTM platform worldwide.
How risky is your portfolio?
Remember that 401k from 2 jobs ago?
Taking on too much risk? Too little risk? Have no idea?
Skip the spreadsheet. Track your investments automatically.
We tally your portfolio fees so you don't have to.
You're probably paying higher fees than you think.
Translate your investment accounts from Martian to English.